000295913 001__ 295913
000295913 005__ 20250123151227.0
000295913 0247_ $$2doi$$a10.1111/apt.18435
000295913 0247_ $$2pmid$$apmid:39686687
000295913 0247_ $$2ISSN$$a0269-2813
000295913 0247_ $$2ISSN$$a1365-2036
000295913 037__ $$aDKFZ-2024-02726
000295913 041__ $$aEnglish
000295913 082__ $$a610
000295913 1001_ $$0P:(DE-He78)cfc349d742aee6cc3394ccaa1ef6494f$$aSeum, Teresa$$b0$$eFirst author$$udkfz
000295913 245__ $$aRisk-Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome.
000295913 260__ $$aOxford$$bBlackwell Science$$c2025
000295913 3367_ $$2DRIVER$$aarticle
000295913 3367_ $$2DataCite$$aOutput Types/Journal article
000295913 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737641509_2893
000295913 3367_ $$2BibTeX$$aARTICLE
000295913 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000295913 3367_ $$00$$2EndNote$$aJournal Article
000295913 500__ $$a#EA:C070#LA:C070# / 2025 Feb;61(4):675-681
000295913 520__ $$aIndividuals with diabetes and metabolic syndrome have an increased risk of colorectal cancer (CRC), suggesting earlier screening than the average-risk population may be warranted.To derive risk-adapted starting ages of CRC screening for people with diabetes or metabolic syndrome.We determined 5-year cumulative risks of CRC at individual ages between 30 and 50 across Europe (overall and individually for Germany, France, the UK and Italy) and North America (the United States and Canada) based on the GLOBOCAN 2022 database. Using risk estimates from meta-analyses (2020-2023), we derived the ages at which individuals with diabetes or metabolic syndrome reach the same CRC risk as the average-risk population at age 50 (aCR50) or 45 (aCR45).Individuals with diabetes were estimated to reach aCR50 at age 47 (95% confidence interval, 45-49) in Europe and 46 (42-49) in North America. For metabolic syndrome, the corresponding ages were 47 (47-48) in Europe and 46 (46-47) in North America. Disparities across countries were minimal, with deviations of up to no more than one year. For screening programmes starting at age 45, corresponding risk-adapted starting ages for people with diabetes or metabolic syndrome were estimated to be 42 (41-44) and 43 (42-43) for Europe and 41 (38-44) and 41 (41-42) for North America, respectively.People with diabetes or metabolic syndrome reach risk levels comparable to the average risk population three to four years earlier. Our results offer empirical guidance for defining risk-adapted starting ages of CRC screening for these high-risk groups.
000295913 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000295913 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000295913 650_7 $$2Other$$acolorectal cancer
000295913 650_7 $$2Other$$adiabetes
000295913 650_7 $$2Other$$ametabolic syndrome
000295913 650_7 $$2Other$$arisk‐adapted screening
000295913 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b1$$udkfz
000295913 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$eLast author$$udkfz
000295913 773__ $$0PERI:(DE-600)2003094-0$$a10.1111/apt.18435$$gp. apt.18435$$n4$$p675-681$$tAlimentary pharmacology & therapeutics$$v61$$x0269-2813$$y2025
000295913 909CO $$ooai:inrepo02.dkfz.de:295913$$pVDB
000295913 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cfc349d742aee6cc3394ccaa1ef6494f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000295913 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000295913 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000295913 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000295913 9141_ $$y2024
000295913 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000295913 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-22$$wger
000295913 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALIMENT PHARM THER : 2022$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000295913 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALIMENT PHARM THER : 2022$$d2023-10-22
000295913 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000295913 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000295913 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000295913 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000295913 980__ $$ajournal
000295913 980__ $$aVDB
000295913 980__ $$aI:(DE-He78)C070-20160331
000295913 980__ $$aI:(DE-He78)HD01-20160331
000295913 980__ $$aUNRESTRICTED